Market Research Report

A quick peek into the report

1.1   Radioligand Therapy: Research Methodology
1.2   Primary Data Sources
1.3   Secondary Data Sources
1.4   Market Estimation Model
1.5   Criteria for Company Profiling

2.1   Product Definition
2.1.1   Inclusion and Exclusion
2.2   Market Scope
2.2.1   Scope of the Study
2.2.2   Key Questions Answered in the Report
2.3   Market Overview
2.3.1   Market Definition
2.3.2   Emerging Applications of Radioligand Therapy
2.3.2.1   Neuroendocrine Neoplasms
2.3.2.2   Prostate Cancer
2.3.2.3   Non-Cancerous Condition
2.3.3   Market Footprint and Growth Potential
2.3.4   COVID-19 Impact on Global Radioligand Therapy Market
2.3.4.1   Impact on Radioligand Therapy
2.3.4.2   Clinical Trial Disruptions and Resumptions

3.1   Overview
3.2   Challenges in Radioligand Therapy Regulatory Approval Pathway
3.3   Regulatory Scenario of Radioligand Therapy
3.4   Legal Requirements and Frameworks in the U.S.
3.4.1   Clinical Trial Authorization
3.4.2   Marketing Authorization
3.4.3   U.S. FDA Guidelines for NDA Submission
3.4.4   Post-Authorization Regulations
3.5   Legal Requirements and Frameworks in Europe
3.5.1   EMA Drug License Application Process
3.5.2   Centralized Procedure
3.5.3   Decentralized Procedure
3.5.4   Mutual-Recognition Procedure
3.5.5   National Procedure
3.6   Legal Requirements and Frameworks in Asia-Pacific
3.6.1   Legal Requirements and Frameworks in Japan

4.1   Radioligand Therapy Pipeline Analysis
4.2   Radioligand Therapy Clinical Trial Design
4.2.1   [Lu-177]-PNT2002
4.2.1.1   Product Profile
4.2.1.2   [Lu-177]-PNT2002 Phase III Study Design
4.2.1.3   [Lu-177]-PNT2002 Efficacy, Safety, and Tolerability (Phase II)
4.2.1.4   177Lu-PNT2002 Pharmacokinetics and Pharmacodynamics Profile (Phase I)
4.2.2   CAM H2
4.2.2.1   Product Profile
4.2.2.2   CAM H2 Preclinical Study Design
4.2.2.3   CAM H2 Phase I/IIa Clinical Study Design
4.2.3   [177Lu]-NeoB
4.2.3.1   Product Profile
4.2.3.2   (177Lu)-NeoB Preclinical Studies
4.2.3.3   (177Lu)-NeoB Phase I/II Clinical Study Design
4.2.4   PNT-2003
4.2.4.1   Product Profile
4.2.4.2   PNT 2003 Ongoing Phase III Clinical Study Design
4.2.5   ITM-11
4.2.5.1   Product Profile
4.2.5.2   ITM-11 Preclinical Proof-of-Concept Studies
4.2.5.3   ITM-11 Phase III Clinical Trial Design
4.2.6   177.Lu FAP-2286
4.2.6.1   Product Profile
4.2.6.2   177.Lu FAP, 2286 Preclinical Study Summary
4.2.6.3   177Lu-FAP-2286 Phase I/IIa Clinical Study Design
4.2.7   FPI-1434
4.2.7.1   Product Profile
4.2.7.2   FPI-1434 Preclinical Study Summary
4.2.7.3   FPI-1434 Phase I/IIa Clinical Study Design
4.2.8   FPI-1966
4.2.8.1   Product Profile
4.2.8.2   FPI-1966 Preclinical Study Summary
4.2.9   177Lu-DOTA-rosopatamab
4.2.9.1   Product Profile
4.2.9.2   TLX591 (177Lu-DOTA-rosopatamab) Ongoing Phase III Clinical Study Design

5.1   Overview
5.2   Impact Analysis
5.3   Market Drivers
5.3.1   Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
5.3.2   Strategic Initiatives by Key Market Players
5.3.3   Rise in Clinical Research Activity
5.4   Market Restraints
5.4.1   High Cost Associated with Treatment and Complex Reimbursement Processes
5.4.2   Increased Competition from Generics
5.5   Market Opportunities
5.5.1   Expanding Radiopharmaceutical Coverage
5.5.2   Role of Radioligand in Drug Discovery

6.1   Overview
6.2   Product Launch
6.3   Product Approvals
6.4   Synergistic Activities
6.5   Mergers and Acquisitions
6.6   Market Share Analysis (by Company), 2020

7.1   Overview
7.2   Prostate Cancer
7.3   Neuroendocrine Tumor (NETs)
7.4   Other

8.1   Overview
8.2   Approved Products
8.2.1   Lutathera
8.2.2   Zytiga
8.2.3   Xtandi
8.2.4   Xofigo
8.3   Potential Pipeline

9.1   Overview
9.2   Prostate-Specific Membrane Antigen
9.3   Ki 67 Expression and Grading
9.4   Cytochrome P450 17A1 Inhibitor

10.1   Overview
10.2   North America
10.2.1   U.S.
10.2.2   Canada
10.3   Europe
10.3.1   Germany
10.3.2   France
10.3.3   U.K.
10.3.4   Italy
10.3.5   Spain
10.3.6   Rest-of-Europe
10.4   Asia-Pacific
10.4.1   Japan
10.4.2   South Korea
10.4.3   Australia
10.4.4   Rest-of-Asia-Pacific (RoAPAC)
10.5   Rest-of-the-World (RoW)

11.1   Overview
11.2   Johnson & Johnson Services, Inc.
11.2.1   Company Overview
11.2.2   Role of Johnson & Johnson Services, Inc. in the Global Radioligand Therapy Market
11.2.3   Product ASP (by Region)
11.2.4   Key Competitors of Company
11.2.5   Financials
11.2.6   Key Insights About the Financial Health of the Company
11.2.7   SWOT Analysis
11.3   Pfizer Inc.
11.3.1   Company Overview
11.3.2   Role of Pfizer Inc. in the Global Radioligand Therapy Market
11.3.3   Product ASP (by Region)
11.3.4   Key Competitors of Company
11.3.5   Financials
11.3.6   Key Insights About Financial Health of the Company
11.3.7   Business Strategies
11.3.7.1   Product Approval
11.3.8   SWOT Analysis
11.4   Amneal Pharmaceuticals LLC.
11.4.1   Company Overview
11.4.2   Role of Amneal Pharmaceuticals LLC. in the Global Radioligand Therapy Market
11.4.3   Key Competitors of Company
11.4.4   Financials
11.4.5   Key Insights About Financial Health of the Company
11.4.6   Business Strategies
11.4.6.1   Product Launch
11.4.7   SWOT Analysis
11.5   Novartis International AG
11.5.1   Company Overview
11.5.2   Role of Novartis International AG in the Global Radioligand Therapy Market
11.5.3   Product ASP (by Region)
11.5.4   Key Competitors of Company
11.5.5   Financials
11.5.6   Key Insights About Financial Health of the Company
11.5.7   Corporate Strategies
11.5.7.1   Mergers and Acquisitions
11.5.7.2   Synergistic Activities
11.5.7.3   Business Expansion and Funding
11.5.8   Business Strategies
11.5.8.1   Product Launches and Approval
11.5.9   SWOT Analysis
11.6   POINT Biopharma Global Inc
11.6.1   Company Overview
11.6.2   Role of POINT Biopharma Global Inc in the Global Radioligand Therapy Market
11.6.3   Key Competitors of Company
11.6.4   Corporate Strategies
11.6.5   SWOT Analysis
11.7   Fusion Pharma
11.7.1   Company Overview
11.7.2   Role of Fusion Pharma in the Global Radioligand Therapy Market
11.7.3   Key Competitors of Company
11.7.4   Financials
11.7.5   Key Insights About the Financial Health of the Company
11.7.6   Corporate Strategies
11.7.6.1   Synergistic Activities
11.7.7   SWOT Analysis
11.8   Clovis Oncology
11.8.1   Company Overview
11.8.2   Role of Clovis Oncology in the Global Radioligand Therapy Market
11.8.3   Key Competitors of Company
11.8.4   Financials
11.8.5   Key Insights About the Financial Health of the Company
11.8.6   Corporate Strategies
11.8.6.1   Mergers and Acquisitions
11.8.7   SWOT Analysis
11.9   Telix Pharmaceuticals
11.9.1   Company Overview
11.9.2   Role of Telix Pharmaceuticals in the Global Radioligand Therapy Market
11.9.3   Key Competitors of Company
11.9.4   Financials
11.9.5   Key Insights About the Financial Health of the Company
11.9.6   Corporate Strategies
11.9.6.1   Mergers and Acquisitions
11.9.6.2   Synergistic Activities
11.9.7   SWOT Analysis
11.10 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
11.10.1   Company Overview
11.10.2   Role of Lantheus Holdings Inc., (Progenics Pharmaceuticals) in the Global Radioligand Therapy Market
11.10.3   Key Competitors of Company
11.10.4   Financials
11.10.5   Key Insights About the Financial Health of the Company
11.10.6   Corporate Strategies
11.10.6.1   Mergers and Acquisitions
11.10.7   SWOT Analysis
11.11   Bayer AG
11.11.1   Company Overview
11.11.2   Role of Bayer AG in the Global Radioligand Therapy Market
11.11.3   Product ASP (by Region)
11.11.4   Key Competitors of Company
11.11.5   Financials
11.11.6   Key Insights About the Financial Health of the Company
11.11.7   Corporate Strategies
11.11.7.1   Mergers and Acquisitions
11.11.7.2   Product Approval
11.11.8   SWOT Analysis
11.12   Molecular Partners
11.12.1   Company Overview
11.12.2   Role of Molecular Partners in the Global Radioligand Therapy Market
11.12.3   Key Competitors of Company
11.12.4   SWOT Analysis

12.1   ITM Isotope Technologies Munich SE
12.1.1   Company Overview
12.1.2   Role of ITM Isotope Technologies Munich SE in the Global Radioligand Therapy Market
12.1.3   Key Competitors of Company
12.1.4   SWOT Analysis
12.2   Curium Pharma
12.2.1   Company Overview
12.2.2   Role of Curium Pharma. in the Global Radioligand Therapy Market
12.2.3   Key Competitors of Company
12.2.4   SWOT Analysis
12.3   Precirix
12.3.1   Company Overview
12.3.2   Role of Precirix in the Global Radioligand Therapy Market
12.3.3   Key Competitors of Company
12.3.4   SWOT Analysis
12.4   Radio Medix
12.4.1   Company Overview
12.4.2   Role of Radio Medix in the Global Radioligand Therapy Market
12.4.3   Key Competitors of Company
12.4.4   SWOT Analysis

Table 1:   Regulatory Scenario of Radioligand Therapy
Table 2:   Emerging Radioligand Therapy Pipeline
Table 3:   Likert Scale
Table 4:   Impact Analysis of Market Drivers
Table 5:   Impact Analysis of Market Restraints
Table 6:   Lutathera ASP by Region
Table 7:   Xtandi: Indications

Figure 1:   Global Cancer Burden, 2020
Figure 2:   Impact Analysis of Market Drivers and Market Challenges on the Global Radioligand Therapy Market
Figure 3:   Revenue Contribution of Different Segments, 2020, 2029, and 2031
Figure 4:   Revenue Contribution of Different Segments, 2020, 2021, and 2031
Figure 5:   Revenue Contribution of Different Segments, 2020, 2021, and 2031
Figure 6:   Global Radioligand Therapy Market (by Region), $Million, 2023-2031
Figure 7:   Global Radioligand Therapy Methodology
Figure 8:   Primary Research Methodology
Figure 9:   Epidemiology-Based Approach
Figure 10:   Global Radioligand Therapy Market Segmentation
Figure 11:   Global Radioligand Therapy Market, $Million, 2020-2031
Figure 12:   Clinical Trial Authorization for Radioligand Therapy in the U.S.
Figure 13:   Steps for Obtaining Marketing Authorization
Figure 14:   U.S. FDA Review Timeline
Figure 15:   EMA Review Timeline
Figure 16:   Radioligand Therapy Global Clinical Trials (by Phase), 2021
Figure 17:   Radioligand Therapy Global Clinical Trials 2021
Figure 18:   177Lu-PSMA-617 (RA101495) Mechanism of Action
Figure 19:   [Lu-177]-PNT2002 Phase III Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer
Figure 20:   177Lu-PNT2002 Phase II Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer
Figure 21:   177Lu-PNT2002 PK/PD Profile Results
Figure 22:   CAM H2 Phase I Portion Clinical Study
Figure 23:   Solid Tumors with Overexpression
Figure 24:   (177Lu)-NeoB Preclinical Studies Framework
Figure 25:   (177Lu)-NeoB Phase I Portion Clinical Study
Figure 26:   Phase III clinical Design for PNT-2003
Figure 27:   Results from ITM-11 Phase III Clinical Trial
Figure 28:   177Lu-FAP-2286 I/IIa Portion Clinical Study
Figure 29:   FPI-1434 I/IIa Portion Clinical Study
Figure 30:   Phase III clinical Design for PNT-2003
Figure 31:   Global Cancer Burden, 2020
Figure 32:   Share of Key Developments, January 2018-February 2022
Figure 33:   Share of Product Approvals (by Company), January 2018-November 2021
Figure 34:   Share of Synergistic Activities (by Company), January 2018-February 2022
Figure 35:   Share of Mergers and Acquisitions (by Company), January 2018-February 2022
Figure 36:   Market Share Analysis of Global Radio Ligand Therapy Market (by Company), 2020
Figure 37:   Revenue Contribution of Different Segments, 2020, 2039, and 2031
Figure 38:   Global Radioligand Therapy Market (Prostate Cancer), $Million, 2020-2031
Figure 39:   Global Radioligand Therapy Market (Neuroendocrine Tumors), $Million, 2025-2031
Figure 40:   Global Radioligand Therapy Market (Others), $Million, 2029-2031
Figure 41:   Global Radioligand Therapy Market Segmentation (by Product)
Figure 42:   Global Radioligand Therapy Market (Approved Products), $Million, 2020-2031
Figure 43:   Global Radioligand Therapy Market (Lutathera), $Million, 2020-2031
Figure 44:   Global Radioligand Therapy Market (Zytiga), $Million, 2020-2031
Figure 45:   Global Radioligand Therapy Market (Xtandi), $Million, 2020-2031
Figure 46:   Global Radioligand Therapy Market (Xofigo), $Million, 2020-2031
Figure 47:   Global Radioligand Therapy Market (Potential Pipeline), $Million, 2024-2031
Figure 48:   Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 3)), $Million, 2024-2031
Figure 49:   Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 2)), $Million, 2029-2031
Figure 50:   Global Radioligand Therapy Market (by Biomarker)
Figure 51:   Global Radioligand Therapy Market (by Biomarker), $Million, 2020 and 2031
Figure 52:   Global Radioligand Therapy Market (Prostate-Specific Membrane Antigen), $Million, 2020-2031
Figure 53:   Global Radioligand Therapy Market (Ki 67 Expression and Grading), $Million, 2020-2031
Figure 54:   Global Radioligand Therapy Market (Cytochrome P450 17A1 Inhibitor), $Million, 2020-2031
Figure 55:   Global Radioligand Therapy Market Snapshot (by Region), $Million, 2020-2031
Figure 56:   Global Radioligand Therapy Market (by Region), $Million, 2020-2031
Figure 57:   North America Radioligand Therapy Market, $Million, 2020-2031
Figure 58:   North America: Market Dynamics
Figure 59:   North America Radioligand Therapy Market (by Country), $Million, 2020-2031
Figure 60:   U.S. Radioligand Therapy Market, $Million, 2020-2031
Figure 61:   Canada Radioligand Therapy Market, $Million, 2020-2031
Figure 62:   Europe Radioligand Therapy Market, $Million, 2020-2031
Figure 63:   Europe: Market Dynamics
Figure 64:   Europe Radioligand Therapy Market (by Country), $Million, 2020-2031
Figure 65:   Germany Radioligand Therapy Market, $Million, 2020-2031
Figure 66:   France Radioligand Therapy Market, $Million, 2020-2031
Figure 67:   U.K. Radioligand Therapy Market, $Million, 2020-2031
Figure 68:   Italy Radioligand Therapy Market, $Million, 2020-2031
Figure 69:   Spain Radioligand Therapy Market, $Million, 2020-2031
Figure 70:   Rest-of Europe Radioligand Therapy Market, $Million, 2020-2031
Figure 71:   Asia-Pacific Radioligand Therapy Market, $Million, 2020-2031
Figure 72:   Asia-Pacific: Market Dynamics
Figure 73:   APAC Radioligand Therapy Market (by Country), $Million, 2020-2031
Figure 74:   Japan Radioligand Therapy Market, $Million, 2020-2031
Figure 75:   South Korea Radioligand Therapy Market, $Million, 2020-2031
Figure 76:   Australia Radioligand Therapy Market, $Million, 2020-2031
Figure 77:   RoAPAC Radioligand Therapy Market, $Million, 2020-2031
Figure 78:   Rest-of-the-World (RoW) Radioligand Therapy Market, $Million, 2020-2031
Figure 79:   Total Number of Companies Profiled
Figure 80:   Johnson & Johnson Services, Inc.: Product Portfolio
Figure 81:   Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2018-2020
Figure 82:   Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 83:   Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 84:   Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 85:   Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 86:   Pfizer Inc.: Commercialized Therapy
Figure 87:   Pfizer Inc.: Overall Financials, $Million, 2018-2020
Figure 88:   Pfizer Inc.: Revenue (by Region), $Million, 2018-2020
Figure 89:   Pfizer Inc.: R&D Expenditure, $Million, 2018-2020
Figure 90:   Pfizer Inc.: SWOT Analysis
Figure 91:   Amneal Pharmaceuticals LLC.: Commercialized Therapy
Figure 92:   Amneal Pharmaceuticals LLC.: Overall Financials, $Million, 2018-2020
Figure 93:   Amneal Pharmaceuticals LLC.: Revenue (by Segment), $Million, 2018-2020
Figure 94:   Amneal Pharmaceuticals LLC.: R&D Expenditure, $Million, 2018-2020
Figure 95:   Amneal Pharmaceuticals.: SWOT Analysis
Figure 96:   Novartis International AG: Commercialized Therapy
Figure 97:   Novartis International AG: Pre-Clinical and Clinical Assets
Figure 98:   Novartis International AG: Overall Financials, $Million, 2018-2020
Figure 99:   Novartis International AG: Revenue (by Segment), $Million, 2018-2020
Figure 100:   Novartis International AG: Revenue (by Region), $Million, 2018-2020
Figure 101:   Novartis International AG: R&D Expenditure, $Million, 2018-2020
Figure 102:   Novartis International AG: SWOT Analysis
Figure 103:   POINT Biopharma Global Inc.: Pipeline Therapy
Figure 104:   POINT Biopharma Global Inc.: SWOT Analysis
Figure 105:   Fusion Pharma: Pipeline Portfolio
Figure 106:   Fusion Pharma: Overall Financials, $Million, 2019-2020
Figure 107:   Fusion Pharma: R&D Expenditure, $Million, 2019-2020
Figure 108:   Fusion Pharma: SWOT Analysis
Figure 109:   Clovis Oncology.: Pipeline Portfolio
Figure 110:   Clovis Oncology.: Overall Financials, $Million, 2018-2020
Figure 111:   Clovis Oncology.: Revenue (by Region), $Million, 2019-2020
Figure 112:   Clovis Oncology.: R&D Expenditure, $Million, 2018-2020
Figure 113:   Clovis Oncology.: SWOT Analysis
Figure 114:   Telix Pharmaceuticals: Product Portfolio
Figure 115:   Telix Pharmaceuticals: Overall Financials, $Million, 2018-2020
Figure 116:   Telix Pharmaceuticals: R&D Expenditure, $Million, 2018-2020
Figure 117:   Telix Pharmaceuticals.: SWOT Analysis
Figure 118:   Lantheus Holdings Inc., (Progenics Pharmaceuticals): Pipeline Portfolio
Figure 119:   Lantheus Holdings Inc. (Progenics Pharmaceuticals): Overall Financials, $Million, 2018-2020
Figure 120:   Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Segment), $Million, 2019 and 2020
Figure 121:   Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Region), $Million, 2018-2020
Figure 122:   Lantheus Holdings Inc. (Progenics Pharmaceuticals): R&D Expenditure, $Million, 2018-2020
Figure 123:   Lantheus Holdings Inc. (Progenics Pharmaceuticals): SWOT Analysis
Figure 124:   Bayer AG.: Product Portfolio
Figure 125:   Bayer AG.: Overall Financials, $Million, 2018-2020
Figure 126:   Bayer AG: Revenue (by Region), $Million, 2018-2020
Figure 127:   Bayer AG.: R&D Expenditure, $Million, 2018-2020
Figure 128:   Bayer AG.: SWOT Analysis
Figure 129:   Molecular Partners.: Product Portfolio
Figure 130:   Molecular Partners.: SWOT Analysis
Figure 131:   ITM Isotope Technologies Munich SE: Product Portfolio
Figure 132:   ITM Isotope Technologies Munich SE: SWOT Analysis
Figure 133:   Curium Pharma.: Product Portfolio
Figure 134:   Curium Pharma: SWOT Analysis
Figure 135:   Precirix: Product Portfolio
Figure 136:   Precirix: SWOT Analysis
Figure 137:   Radiomedix: Product Portfolio
Figure 138:   RadioMedix: SWOT Analysis

Market Report Coverage

Radioligand Therapy Market
Base Year	2020	Market Size in 2021	$10,554.0 Million
Forecast Period	2021-2031	Value Projection and Estimation by 2031	$16,658.4 Million
CAGR During Forecast Period	4.67%	Number of Tables	07
Number of Pages	182	Number of Figures	138
Market Segmentation	• Product (Approved Products and Potential Pipeline) • Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others) • Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
Regional Segmentation	• North America - U.S., Canada • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe • Asia-Pacific - Japan, South Korea, Australia, and Rest-of-Asia-Pacific • Rest-of-the-World
Market Growth Drivers	• Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer • Strategic Initiatives by Key Market Players • Rise in Clinical Research Activity
Market Challenges	• High Cost Associated with Treatment and Complex Reimbursement Processes • Increased Competition from Generics
Market Opportunities	• Expanding Radiopharmaceutical Coverage • Role of Radioligand in Drug Discovery
Key Companies Profiled	Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc. (Progenics Pharmaceuticals), Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, Radio Medix

Key Questions Answered in this Report:

•   How is radioligand therapy revolutionizing oncology?
•   What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
•   What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
•   How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
•   What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
•   What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
•   What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
•   How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o   Products (Approved Products and Potential Pipeline)
o   Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
o   Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
o   Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
•   What are the growth opportunities for the radioligand therapy companies in the region of their operation?
•   Who are the leading players with significant offerings in the global radioligand therapy market?
•   Which companies are anticipated to be highly disruptive in the future, and why?

Report Summary

Market Overview

Radioligand therapeutics, also known as radiopharmaceuticals, which show antitumor effects, has seen rapid development over the past decade. Although some therapies are already approved for human use, many more are in the clinical trial and will enter clinical practice in the next 2-7 years, potentially introducing new therapeutic choices for patients. Despite this innovation, several challenges remain, including supply chain, logistics, regulatory issues, and education and training. The current market for radioligand therapy is majorly dominated by manufacturers such as Novartis AG, Pfizer Inc, Johnson & Johnson Services, Inc, Telix Pharmaceuticals, Lantheus Holdings Inc., (Progenics Pharmaceuticals), Molecular Partners AG, Clovis Oncology Inc., Fusion Pharma, Point Biopharma, Precirix, ITM Isotope Technologies Munich SE, Curium Pharma, and RadioMedix. The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031.

Competitive Landscape

The global radioligand therapy market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the innovation in radioligand therapy from different sample types. Key market players of the global radioligand therapy market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2018-February 2022. The inclination of companies toward product launches and product approval suggests that the companies are involved in continuously bringing new products to the market to radioligand therapy, which is primarily attributed to a rising prevalence of cancer, rising clinical research activity, and rising key players' initiatives are driving the market.